Wiktor Orlof

Dr. Wiktor Orlof


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Psychiatria Polska
Verified
Journal Article
Open access
EREmil Rozenek
Emil Rozenek
WOWiktor Orlof
Wiktor Orlof
ZNZuzanna Nowicka
Zuzanna Nowicka
Karolina WilczyńskaKarolina Wilczyńska
Karolina Wilczyńska
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Niemożność mówienia w pewnych sytuacjach − tak najkrócej można scharakteryzować mutyzm wybiórczy (ang. Selective mutism, SM), który według najnowszych klasyfikacji (DSM-V, ICD-11) należy do spektrum zaburzeń lękowych. Pojawienie się mutyzmu wybiórczego w okresie wczesnodziecięcym może zaburzać dalszy rozwój, a także niekorzystnie wpływać na osiągnięcia edukacyjne. Zarówno psychiatrzy, jak i lekarze innych specjalizacji, logopedzi, pielęgniarki i nauczyciele powinni posiadać odpowiednią wiedzę na temat tego zaburzenia, ponieważ wcześnie podjęte leczenie wiąże się z lepszym rokowaniem. Celem niniejszego przeglądu literatury jest przybliżenie współczesnego spojrzenia na stosunkowo rzadki zespół psychopatologiczny jakim jest mutyzm wybiórczy. W świetle najnowszych badań dotyczących etiologii SM sam objaw mutyzmu wydaje się być jedynie wykładnikiem kryjącej się pod nim heterogennej grupy zaburzeń. Opierając się na psychopatologii rozwoju można wnioskować, że wzajemne powiązania między piętrzącymi się nieprawidłowościami sprzyjają ujawnieniu się SM w przełomowym okresie życia. Złożoność etiologiczna sugeruje multimodalne podejście do pacjenta w procesie diagnostyczno-terapeutycznym, co jest postulowane przez wielu autorów.

5 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JŚJustyna Śniadach
Justyna Śniadach
WOWiktor Orlof
Wiktor Orlof
JSJustyna Sołowiej-Chmiel
Justyna Sołowiej-Chmiel
AKAleksandra Kicman
Aleksandra Kicman
SSSylwia Szymkowiak
Sylwia Szymkowiak
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Chemsex is a phenomenon involving the intentional use of psychoactive substances before or during sexual activity, especially among men who have sex with men (MSM). It is associated with various health risks, including substance dependence, risky sexual behaviors, and both mental and somatic disorders. Despite its growing prevalence and public health relevance, chemsex lacks a clear definition and is not recognized as a distinct diagnostic entity. This narrative review synthesizes clinical, epidemiological, and technological evidence on chemsex; argues for its classification as a form of mixed addiction; and preliminarily proposes diagnostic criteria for a potential entity in the International Classification of Diseases, 12th Revision (ICD-12). This paper highlights key psychotropic substances used in chemsex, patterns of use, and their neurobiological, psychological, and behavioral consequences. It explores the relationship between chemsex and compulsive sexual behavior disorder (CSBD), current diagnostic frameworks (ICD-10 and ICD-11), and challenges in clinical practice. Therapeutic strategies discussed include cognitive behavioral therapy (CBT), digital interventions, and emerging applications of artificial intelligence (AI) in prevention and treatment. Attention is also given to epidemiological trends, sociocultural influences, and barriers to seeking help. This review concludes by identifying research gaps and advocating for a more integrated, multidimensional approach to classifying and treating chemsex-related syndromes.

1 January 2021 in Postępy Psychiatrii i Neurologii
Verified
Journal Article
Open access
PDF file
WOWiktor Orlof
Wiktor Orlof
EREmil B. Rozenek
Emil B. Rozenek
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
BSBogumiła Szewczak
Bogumiła Szewczak
Purpose Dissociative identity disorder (DID) is characterized by the presence of a minimum of two identities. Each identity has different fixed patterns of perception, establishing relationships, and thinking about itself and the environment in which it lives. The etiology...

16 December 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
WOWiktor Orlof
Wiktor Orlof
Jerzy LadnyJerzy Ladny
Jerzy Ladny
Daniel MichalakDaniel Michalak
Daniel Michalak
MŻMałgorzata Żendzian-Piotrowska
Małgorzata Żendzian-Piotrowska
Anna ZalewskaAnna Zalewska
Anna Zalewska
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
Protein glycation and oxidation contribute to the pathogenesis of neurodegenerative diseases. This study evaluated the antiglycative and antioxidative effects of donepezil, rivastigmine, galantamine, memantine, lamotrigine, sodium valproate, and carbamazepine using bovine serum albumin (BSA) as a model protein. Glycation was induced with fructose, ribose, or methylglyoxal (MGO), and oxidation with chloramine T (ChT). Concentrations of glycation products—Amadori products (APs), amyloid cross-β structure (βA), argpyrimidine (ARG), crossline (CRO), vesperlysine (VES), pentosidine (PEN), total AGEs and glycoxidation products—dityrosine (DT), kynurenine (KN), N-formylkynurenine (NFK) as well as oxidation biomarkers, total thiols (TTs), protein carbonyls (PCs), and advanced oxidation protein products (AOPPs), were determined via spectrophotometric and spectrofluorimetric methods. Molecular docking and a systematic literature review (PRISMA) complemented the experimental data. Lamotrigine showed the strongest antiglycative and antioxidative effects, surpassing aminoguanidine in reducing ARG, PEN, DT, and NFK levels. In contrast, donepezil markedly increased APs, βA, ARG, VES, DT, and PEN, suggesting proglycative and pro-oxidative activity. Docking revealed a high affinity of donepezil for RAGE (–7.2 kcal/mol), possibly explaining its impact on carbonyl stress. Overall, anti-dementia drugs showed weak to moderate antiglycative potential, with lamotrigine being the most effective.

27 April 2026 in Redox Biology
Verified
Journal Article
Open access
WOWiktor Orlof
Wiktor Orlof
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
This review integrates current findings on protein glycation, glycoxidation, and carbonyl stress in selected neurodegenerative and neuropsychiatric disorders, with a particular focus on mechanistic pathways relevant to Alzheimer's disease (AD), Parkinson's disease (PD), schizophrenia, and depression, as well as on their potential clinical relevance, including biomarker development and antiglycation interventions. These processes are increasingly recognised as cross-cutting features in various neuropsychiatric conditions. Despite this mechanistic relevance, no neuropsychiatric drugs have been convincingly demonstrated to exert direct antiglycation activity in vivo. The majority of published findings concern indirect modulation of carbonyl stress, redox imbalance, and advanced glycation end products (AGEs) and their receptor (RAGE) signalling rather than direct inhibition of glycation. AGEs, particularly the lysine-derived adducts Nε-(carboxyethyl)lysine (CEL) and Nε-(carboxymethyl)lysine (CML), show potential as diagnostic and prognostic biomarkers in neurodegenerative diseases, although further clinical validation is required. Modulation of protein glycation, carbonyl stress, and AGE-RAGE signalling has emerged as a common mechanistic denominator in various therapeutic strategies explored in neuropsychiatric disorders.

11 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WOWiktor Orlof
Wiktor Orlof
JSJustyna Sołowiej-Chmiel
Justyna Sołowiej-Chmiel
Napoleon WaszkiewiczNapoleon Waszkiewicz
Napoleon Waszkiewicz
Introduction: Dissociative identity disorder (DID) is a condition characterized by the presence of at least two distinct identities. The experience of severe trauma, particularly in childhood and especially related to physical and emotional abuse, is considered the most common etiological source, leading to the development of dissociative mechanisms, as confirmed by both the literature and the authors’ research findings. The diagnosis of DID is complex and requires a multimodal approach. This report presents a comprehensive psychiatric and psychological assessment using an integrated diagnostic framework combining clinical observation, psychometric evaluation, and neuroimaging. Methods: A 33-year-old woman presented to the Psychiatric Clinic due to numerous amnestic episodes and recurrent identity switches, resulting in a lack of continuity in autobiographical memory and heterogeneous functioning. The patient had previously been treated at the Mental Health Outpatient Clinic with suspected schizophrenia. The patient’s history was difficult to collect and switches between identities were observed, with a marked change in behavior. The patient declared the presence of 46 different personalities. The stories she reported changed, depending on the dominant identity, each of which varied in terms of gender, name, sexual orientation, interests, or pattern of behavior. Results: The patient underwent a thorough laboratory diagnosis, including toxicologic diagnosis, neuroimaging, and psychological diagnosis. On the basis of the information collected, based on the ICD-10 Classification, the diagnosis was: F44.8—dissociative identity disorder. Discussion: The clinical entity described by the authors still poses many diagnostic and therapeutic uncertainties. In the literature, we do not find a case description that holistically encompasses DID. Therefore, the following description represents a unique bibliographic item that is useful to professionals in planning medical and therapeutic care.